- Home
- SOPH vs GOSS Comparison
SOPH vs GOSS Comparison
Compare SOPH & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | GOSS |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.4M | 796.2M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SOPH | GOSS |
|---|---|---|
| Price | $4.66 | $2.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.00 | ★ $8.60 |
| AVG Volume (30 Days) | 56.4K | ★ 4.4M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $73,297,000.00 | $44,051,000.00 |
| Revenue This Year | $18.32 | N/A |
| Revenue Next Year | $15.61 | $6.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.66 | N/A |
| 52 Week Low | $2.58 | $0.76 |
| 52 Week High | $5.30 | $3.87 |
Technical Indicators
Market Signals| Indicator | SOPH | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 39.59 |
| Support Level | $4.56 | $3.04 |
| Resistance Level | $4.82 | $3.87 |
| Average True Range (ATR) | 0.18 | 0.29 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 42.41 | 1.49 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.